Related Experiment Video
Updated: Jul 24, 2025

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response
Abstract:
Dysregulated pre-mRNA splicing and metabolism are two hallmarks of MYC-driven cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and therapies is poorly understood. Here, we demonstrate that Jumonji Domain Containing 6, Arginine Demethylase and Lysine Hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven neuroblastoma. JMJD6 cooperates with MYC in cellular transformation by physically interacting with RNA binding proteins involved in pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two isoforms of glutaminase (GLS), namely kidney-type glutaminase (KGA) and glutaminase C (GAC), which are rate-limiting enzymes of glutaminolysis in the central carbon metabolism in neuroblastoma. Further, we show that JMJD6 is correlated with the anti-cancer activity of indisulam, a "molecular glue" that degrades splicing factor RBM39, which complexes with JMJD6. The indisulam-mediated cancer cell killing is at least partly dependent on the glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a cancer-promoting metabolic program is associated with alternative pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven cancers.
Insights
Jumonji Domain Containing 6 (JMJD6) connects pre-mRNA splicing and metabolism in MYC-driven cancers. Targeting JMJD6 may offer a new therapeutic strategy for neuroblastoma by impacting glutamine metabolism.
Area of Science:
- Oncology
- Molecular Biology
- Metabolism
Background:
- MYC-driven cancers exhibit dysregulated pre-mRNA splicing and metabolism.
- Therapeutic strategies targeting these processes are under investigation.
- The interplay between splicing and metabolism under oncogenic stress is unclear.
Conclusions:
- JMJD6 orchestrates a cancer-promoting metabolic program linked to alternative pre-mRNA splicing.
- Targeting JMJD6 presents a potential therapeutic strategy for MYC-driven cancers, particularly neuroblastoma.
Related Concept Videos
RNA Splicing
Pre-mRNA Processing: RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
MicroRNAs
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

